| 1. |
劉俊, 裘正軍, 江技, 等. Akt和磷酸化Aktl在胰腺癌組織中的表達及意義[J].中華胰腺病雜志, 2010, 10(2):128-130.
|
| 2. |
肖國華, 王忠保. PKB/Akt在糖尿病及其血管并發癥中的調節作用[J].醫學研究雜志, 2010, 39(1):13-15.
|
| 3. |
Zhou MS, Schulman IH, Raij L.Role of angiotensinⅡand oxidative stress in vascular insulin resistance linked to hypertension[J]. Am J Physiol Heart Circ Physiol, 2009, 296(3):H833-839.
|
| 4. |
黎笑楠, 龐東渤, 趙海雁, 等.坎地沙坦治療大鼠糖尿病視網膜病變的作用機制[J].國際眼科雜志, 2011, 11(2):226-228.
|
| 5. |
譚歆, 龐東渤, 趙海燕, 等.坎地沙坦對糖尿病大鼠視網膜VEGF和MCP-1表達的影響[J].國際眼科雜志, 2011, 11(3):406-408.
|
| 6. |
Guha M, Mackman N. The phosph atidy linositol 3-kinase-Akt. pathway limits lipopoly saccharide activation of signaling pathways and expression of inflame matory mediators in humanmonocytic cells[J]. J Biol Chem, 2002, 277(35):32124-32132.
|
| 7. |
Kobayashi T, Taguchi K, Yasuhiro T, et al. Impairment of PI3K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model[J]. Hypertension, 2004, 44(6):956-962.
|
| 8. |
蘭超, 李莉.坎地沙坦對充血性心力衰竭的治療作用及對內皮素和心鈉素水平的影響[J].中國急救醫學, 2006, 26(5):323-325.
|
| 9. |
Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2):a randomised placebo-controlled trial[J]. Lancet, 2008, 372(9647):1385-1393.
|
| 10. |
Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes[J].Kidney Int, 2002, 61(3):1086-1097.
|